[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362712-105":59,"doc-detail-362712-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-prognostic-and-immune-infiltration-assessment-of-lgals3bp-in-pan-cancer-patients","Comprehensive Prognostic and Immune Infiltration Assessment of LGALS3BP in Pan-Cancer Patients","","LGALS3BP is a multifunctional glycoprotein highly expressed in cancers and linked to poor clinical outcomes, yet a cross-cancer comprehensive view is limited. This study integrates RNA-seq, tumor mutation burden (TMB), microsatellite instability (MSI), and clinical data from TCGA covering 33 cancer types. Pan-cancer mutations are obtained from cBioPortal, while tumor microenvironment is analyzed using ESTIMATE and CIBERSORT, with single-cell work via TISCH2. Protein–protein interactions and functional enrichment use STRING. Results show cancer-type–specific expression patterns, prognostic associations, and relationships with TMB, MSI, immune infiltration, and immune cell subsets, supporting LGALS3BP as a potential pan-cancer prognostic marker despite needing further experimental validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-prognostic-and-immune-infiltration-assessment-of-lgals3bp-in-pan-cancer-patients/362712/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-prognostic-and-immune-infiltration-assessment-of-lgals3bp-in-pan-cancer-patients/362712.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is LGALS3BP and why is it important in cancers?","Question",{"text":112,"@type":113},"LGALS3BP is a multifunctional glycoprotein highly expressed in human cancers and associated with poor clinical outcomes. The study focuses on its broad relevance across cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was LGALS3BP analyzed across pan-cancer data?",{"text":117,"@type":113},"The analysis used RNA sequencing, TMB, MSI, and clinical data from TCGA covering 33 cancer types. It also incorporated cBioPortal mutation data and microenvironment estimation with ESTIMATE and CIBERSORT.",{"name":119,"@type":110,"acceptedAnswer":120},"What relationships were observed between LGALS3BP and the tumor immune environment?",{"text":121,"@type":113},"LGALS3BP expression was linked to tumor immune infiltration and specific immune cell populations. It was reported to affect TMB and MSI and to interact with immune-related molecules, with single-cell data supporting elevated expression in certain cell types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362712,1790648997,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Yun etal. Discover Oncology (2026) 17:448 [https://doi.org/10.1007/s12672-026-04622-z](https://doi.org/10.1007/s12672-026-04622-z)  \nDiscover Oncology  \nANALYSIS Open Access  \nComprehensive prognostic and immune infiltration assessment of LGALS3BP in pan-  \ncancer patients  \nDuo Yun1,2, Qier Mu3, Yanli Li4, Wenpeng Wang5*, Riwen An3* and Feng Wang6*  \n*Correspondence:  \nWenpeng Wang [wangwenpeng@tjmuch.com](wangwenpeng@tjmuch.com)[ ](wangwenpeng@tjmuch.com)Riwen An [15248695413@163.com](15248695413@163.com)[ ](15248695413@163.com)Feng Wang [fwang40@emory.edu](fwang40@emory.edu)  \nFull list of author information is available at the end of the article  \nAbstract  \nLGALS3BP, a multifunctional glycoprotein, is highly expressed in human cancers and associated with poor clinical outcomes. However, there is a lack of comprehensive analysis across multiple cancer types.This study utilized RNA sequencing, TMB, MSI, and clinical data from TCGA and clinical profiles, covering 33 cancer types. The expression of LGALS3BP was analyzed and pan-cancer mutation information was obtained from cBioPortal. Tumor microenvironment analysis employed the “ESTIMATE”and CIBERSORT algorithms. Single-cell analysis was performed using the TISCH2 database. protein–protein interactions and functional enrichment analysis utilized the STRING database. LGALS3BP expression varied in different tumor types, being higher in BLCA, BRCA, ESCA, GBM, HNSC, KIRC, LUAD, and UCEC. It was associated with prognosis, with higher levels indicating worse survival in some cancers. LGALS3BP also affects TMB, MSI, tumor immune infiltration and the presence of specific immune cell populations. It interacted with immune stimulators, MHCs, and immune inhibitors. Single-cell analyses showed the elevated expression in certain cell types, and protein–protein interaction analysis revealed its involvement in immune response and tumor microenvironment. LGALS3BP expression is associated with patient outcomes and tumor immune response in various cancer types, highlighting its potential as a prognostic marker. However, additional experimental validation is needed to confirm these findings.  \nKeywords LGALS3BP, Pan-cancer, Prognostic marker, Tumor mutation status, Tumor microenvironment, Single-cell analyses  \n1 Introduction  \nCancer remains a leading cause of global morbidity and mortality. In 2022, nearly 20 million new cancer cases and approximately 10 million cancer-related deaths were reported worldwide, and this burden is expected to increase substantially in the coming decades [1, 2]. Despite advances in cancer diagnosis and treatment, overall patient prognosis remains unsatisfactory, underscoring the urgent need for improved molecular understanding and robust biomarkers to support more effective prevention, early detection, and personalized therapy.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nYun et al. Discover Oncology (2026) 17:448 Page 2 of 19  \nLectin galactoside","cbCaiv8RylvbxT3s","https://ap.wps.com/l/cbCaiv8RylvbxT3s","pdf",5677255,"English","# Abstract\n# Keywords\n# 1 Introduction","[{\"question\":\"What is LGALS3BP and why is it important in cancers?\",\"answer\":\"LGALS3BP is a multifunctional glycoprotein highly expressed in human cancers and associated with poor clinical outcomes. The study focuses on its broad relevance across cancer types.\"},{\"question\":\"How was LGALS3BP analyzed across pan-cancer data?\",\"answer\":\"The analysis used RNA sequencing, TMB, MSI, and clinical data from TCGA covering 33 cancer types. It also incorporated cBioPortal mutation data and microenvironment estimation with ESTIMATE and CIBERSORT.\"},{\"question\":\"What relationships were observed between LGALS3BP and the tumor immune environment?\",\"answer\":\"LGALS3BP expression was linked to tumor immune infiltration and specific immune cell populations. It was reported to affect TMB and MSI and to interact with immune-related molecules, with single-cell data supporting elevated expression in certain cell types.\"}]","Comprehensive Prognostic and Immune Infiltration Assessment of LGALS3BP in Pan-Cancer Patients | PDF",1790148860,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2950673d5864ccfc2e3def7ff1ba319.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d992307d44cac931d66be34f882d2a04.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2df41e752a776883fcfd3675fe57312.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f094b139fd17ca66784caefaaf0d2995.webp",980,1306]